|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
|
|
2
|
Morimoto M, Numata K, Kondo M, et al:
Higher discontinuation and lower survival rates are likely in
elderly Japanese patients with advanced hepatocellular carcinoma
receiving sorafenib. Hepatol Res. 41:296–302. 2011. View Article : Google Scholar
|
|
3
|
Meric F, Patt YZ, Curley SA, et al:
Surgery after downstaging of unresectable hepatic tumors with
intra-arterial chemotherapy. Ann Surg Oncol. 7:490–495. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Forner A, Reig ME, de Lope CR, et al:
Current strategy for staging and treatment: the BCLC update and
future prospects. Semin Liver Dis. 30:61–74. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: from genes to environment. Nat Rev Cancer.
6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Park IK, Morrison SJ and Clarke MF: Bmi1,
stem cells, and senescence regulation. J Clin Invest. 113:175–179.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yonemitsu Y, Imazeki F, Chiba T, et al:
Distinct expression of polycomb group proteins EZH2 and BMI1 in
hepatocellular carcinoma. Hum Pathol. 40:1304–1311. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sasaki M, Ikeda H, Itatsu K, et al: The
overexpression of polycomb group proteins Bmi1 and EZH2 is
associated with the progression and aggressive biological behavior
of hepatocellular carcinoma. Lab Invest. 88:873–882. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chiba T, Miyagi S, Saraya A, et al: The
polycomb gene product BMI1 contributes to the maintenance of
tumor-initiating side population cells in hepatocellular carcinoma.
Cancer Res. 68:7742–7749. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Munoz M, Henderson M, Haber M, et al: Role
of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB
Life. 59:752–757. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baguley BC: Multidrug resistance in
cancer. Methods Mol Biol. 596:1–14. 2010. View Article : Google Scholar
|
|
12
|
Seth P: Vector-mediated cancer gene
therapy: an overview. Cancer Biol Ther. 4:512–517. 2005. View Article : Google Scholar
|
|
13
|
Baggetto LG, Gambrelle J, Dayan G, et al:
Major cytogenetic aberrations and typical multidrug resistance
phenotype of uveal melanoma: current views and new therapeutic
prospects. Cancer Treat Rev. 31:361–379. 2005. View Article : Google Scholar
|
|
14
|
Izquierdo M: Short interfering RNAs as a
tool for cancer gene therapy. Cancer Gene Ther. 12:217–227. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duxbury MS, Matros E, Ito H, Zinner MJ, et
al: Systemic siRNA-mediated gene silencing: a new approach to
targeted therapy of cancer. Ann Surg. 240:667–674. 2004.PubMed/NCBI
|
|
16
|
Yu C, Zhang X, Sun G, et al: RNA
interference-mediated silencing of the polo-like kinase 1 gene
enhances chemosensitivity to gemcitabine in pancreatic
adenocarcinoma cells. J Cell Mol Med. 12:2334–2349. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh A, Boldin-Adamsky S, Thimmulappa RK,
et al: RNAi-mediated silencing of nuclear factor
erythroid-2-related factor 2 gene expression in non-small cell lung
cancer inhibits tumor growth and increases efficacy of
chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dong K, Wang R, Wang X, et al:
Tumor-specific RNAi targeting eIF4E suppresses tumor growth,
induces apoptosis and enhances cisplatin cytotoxicity in human
breast carcinoma cells. Breast Cancer Res Treat. 113:443–456. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jia L, Wang H, Qu S, et al: CD147
regulates vascular endothelial growth factor-A expression,
tumorigenicity, and chemosensitivity to curcumin in hepatocellular
carcinoma. IUBMB Life. 60:57–63. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Xiao XQ, Deng CM, et al:
Downregulation of xIAP expression by small interfering RNA inhibits
cellular viability and increases chemosensitivity to methotrexate
in human hepatoma cell line HepG2. J Chemother. 18:525–531. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dutton A, Woodman CB, Chukwuma MB, et al:
Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and
regulates the expression of viral target genes in Hodgkin lymphoma
cells. Blood. 109:2597–2603. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Breuer RH, Snijders PJ, Sutedja GT, et al:
Expression of the p16(INK4a) gene product, methylation of the
p16(INK4a) promoter region and expression of the polycomb-group
gene BMI-1 in squamous cell lung carcinoma and premalignant
endobronchial lesions. Lung Cancer. 48:299–306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bhattacharya R, Kwon J, Ali B, et al: Role
of hedgehog signaling in ovarian cancer. Clin Cancer Res.
14:7659–7666. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song LB, Li J, Liao WT, et al: The
polycomb group protein Bmi-1 represses the tumor suppressor PTEN
and induces epithelial-mesenchymal transition in human
nasopharyngeal epithelial cells. J Clin Invest. 119:3626–3636.
2009. View
Article : Google Scholar
|
|
25
|
Song LB, Zeng MS, Liao WT, et al: Bmi-1 is
a novel molecular marker of nasopharyngeal carcinoma progression
and immortalizes primary human nasopharyngeal epithelial cells.
Cancer Res. 66:6225–6232. 2006. View Article : Google Scholar
|
|
26
|
Kim JH, Yoon SY, Jeong SH, et al:
Overexpression of Bmi-1 oncoprotein correlates with axillary lymph
node metastases in invasive ductal breast cancer. Breast.
13:383–388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qin L, Zhang X, Zhang L, et al:
Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis
in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun.
371:531–535. 2008. View Article : Google Scholar : PubMed/NCBI
|
